1. A multiplex droplet digital PCR assay for non-invasive prenatal testing of fetal aneuploidies
- Author
-
Chen Xihua, Chao Lu, Zhu Lingxiang, Chianru Tan, Gao Na, Cao Zongfu, Yang Wenjun, Gao Huafang, Fang Wang, Guo Yong, Xiurui Zhu, and Dong Wang
- Subjects
Male ,Disease status ,Chromosomes, Human, Pair 21 ,02 engineering and technology ,Computational biology ,01 natural sciences ,Biochemistry ,Analytical Chemistry ,Pregnancy ,Prenatal Diagnosis ,Multiplex polymerase chain reaction ,Electrochemistry ,Humans ,Environmental Chemistry ,Medicine ,Statistical analysis ,Digital polymerase chain reaction ,Multiplex ,Locked nucleic acid ,Spectroscopy ,Plasma samples ,business.industry ,010401 analytical chemistry ,Non invasive ,Aneuploidy ,021001 nanoscience & nanotechnology ,0104 chemical sciences ,Female ,0210 nano-technology ,business ,Multiplex Polymerase Chain Reaction - Abstract
Higher multiplexing in droplet digital PCR (ddPCR) can simplify the detection process of ddPCR-based non-invasive prenatal testing (NIPT) and improve its reliability, making it a practical approach in clinical practice. However, a high level of multiplex ddPCR-based NIPT has rarely been reported. In this study, we developed a multiplex ddPCR assay using universal locked nucleic acid (LNA) probes to reliably identify fetal aneuploidies. We first performed statistical analysis based on the Poisson distribution to evaluate the required number of target DNA molecules and the total number of droplets for a ddPCR assay. Next, we designed two sets of primers and probes to quantify cfDNA from chromosomes 21 and 18 and then determined the disease status of a sample. Finally, we evaluated our multiplex ddPCR assay with 60 clinical plasma samples. All of the 60 clinical samples were correctly identified. The accessibility and cost-effectiveness of our multiplex ddPCR-based NIPT make it a competitive prenatal testing method in clinical use.
- Published
- 2019